This is comparable to Hoffmann et al. who found only one anti-dementia drug in over 90% of his patients and Truter who only reported 5.3% of patients that were prescribed more than one active ingredient for Alzheimer's disease during one year (mostly donepezil or galantamine, and memantine) [38,39], whereas Formiga found combined therapy of cholinesterase inhibitors in 15.5% of patients [35]. This evidence concerns the gene BCHE and early-onset autosomal dominant Alzheimer disease.